How much revenue does Zhejiang Jingxin Pharmaceutical make?

Zhejiang Jingxin Pharmaceutical reported 4.16 billion CNY in revenue for fiscal year 2024, up 4.0% from 4.00 billion CNY in fiscal year 2023. In Q2 2025 revenue was 1.06 billion CNY.

What is Zhejiang Jingxin Pharmaceutical's largest business segment?

Finished drug Business, with 2.59 billion CNY or 47% of segment revenue in fiscal year 2025. Next: Active Pharmaceutical Ingredient Sales (34%) and Medical device Business (13%).

Where does Zhejiang Jingxin Pharmaceutical make most of its revenue?

East China: 35% of revenue by region in fiscal year 2025, followed by Overseas (21%).

What companies are similar to Zhejiang Jingxin Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Shanghai Haixin Group Co., Ltd. (600851.SS), Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS), Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ), Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ).

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) Stock

About Zhejiang Jingxin Pharmaceutical Co., Ltd.

Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemir...

At a glance

Zhejiang Jingxin Pharmaceutical reported revenue of 4.16 billion CNY for fiscal year 2024, up 4.0% from fiscal year 2023, and net income of 711.96 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 1.06 billion CNY, down 2.6% from a year before. Its largest business segment, Finished drug Business, brought in 47% of segment revenue in fiscal year 2025; East China was the largest region with 35%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.